Condensed Consolidated Statements Of Cash Flows (USD $) In Thousands, unless otherwise specified	3 Months Ended
	Mar. 31, 2013	Mar. 31, 2012
Operating activities
Net income	$ 43,425	$ 27,681
Adjustments to reconcile net income to net cash provided by operating activities:
Amortization of intangible assets	19,555	13,513
Depreciation	575	186
Loss on disposal of property and equipment	40	0
Share-based compensation	8,757	3,281
Excess tax benefit from share-based compensation	(889)	(1,914)
Acquisition accounting inventory fair value step-up	1,545	2,369
Change in fair value of contingent consideration	4,500	0
Deferred income taxes	(3,874)	0
Provision for losses on accounts receivable and inventory	142	43
Other non-cash transactions	1,975	42
Changes in assets and liabilities:
Accounts receivable	(18,911)	(8,794)
Inventories	1,231	(101)
Prepaid expenses and other current assets	(6,272)	(2,217)
Other long-term assets	(999)	(298)
Accounts payable	16,158	4,649
Accrued liabilities	(2,660)	(6,539)
Income taxes payable	(1,397)	0
Deferred revenue	(207)	(285)
Other non-current liabilities	3,196	(1)
Liability under government settlement	0	(7,320)
Net cash provided by operating activities	65,890	24,295
Investing activities
Cash acquired from merger with Azur Pharma	0	81,751
Purchases of marketable securities	0	(30,628)
Proceeds from sale of marketable securities	0	15,082
Proceeds from maturities of marketable securities	0	17,838
Purchases of intangible assets	(1,300)	0
Purchases of property and equipment	(1,143)	(285)
Purchase of product rights	0	(1,250)
Net cash provided by (used in) investing activities	(2,443)	82,508
Financing activities
Proceeds from exercise of share options and warrants	9,609	5,160
Payment of employee withholding taxes related to share-based awards	(1,427)	(25,299)
Excess tax benefit from share-based compensation	889	1,914
Repayment of long-term debt	(5,938)	0
Net cash provided by (used in) financing activities	3,133	(18,225)
Effect of exchange rates on cash and cash equivalents	(3,265)	0
Net increase in cash and cash equivalents	63,315	88,578
Cash and cash equivalents, at beginning of period	387,196	82,076
Cash and cash equivalents, at end of period	$ 450,511	$ 170,654